Received Feb 10, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 9494P | IM |
Inappropriate route of administration/we administer that vaccine IM; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a adult patient who received MMR (Priorix) (batch number 9494P, expiry date 01-APR-2027) for prophylaxis. On 06-FEB-2026, the patient received Priorix (intramuscular). On 06-FEB-2026, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Inappropriate route of administration/we administer that vaccine IM). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 06-FEB-2026 The pharmacist called to report the intramuscular administration of Priorix. The reporter asked that the patient still going to have protection, or she need to be revaccinated. The patient's date of birth and gender were asked but were not provided, as the reporter did not want to share patient details over the phone. No further details were provided.